Dianthus Therapeutics posts 75% interim response rate in CIDP Phase 3 trial
On June 11, 2026, Dianthus Therapeutics posted an updated corporate presentation with interim responder analysis for the first 40 patients to complete Part A of the Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP). The presentation reports a 75% response rate, and the company says it supports potential best-in-disease efficacy. The filing notes the analysis covers a limited number of patients and may not predict results for remaining Part A patients or Part B.
Key points
- Observed 75% response rate from the first 40 participants to complete CAPTIVATE Part A, per the presentation.
- Company guidance: Phase 3 CIDP Part B top-line guidance by year-end 2026.
- Cash, cash equivalents and investments of about $1.2 billion as of March 31, 2026, with runway expected into 2030.
- Presentation filed as Exhibit 99.1, dated June 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.